Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Awada

Showing results (151-160 of 210) with videos related to

Pageof 21
Sort By:
Medical Oncology (Northwood, London, England)|July 8, 2011
Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: an expert agreementC Porta, G Tortora, C Linassier, et al.
Anti-Cancer Drugs|May 29, 2004
Prolonged schedule of temozolomide (Temodal) plus liposomal doxorubicin (Caelyx) in advanced solid cancersA Awada, T Gil, F Sales, et al.
Neuroepidemiology|January 1, 1993
A community survey of neurological disorders in Saudi Arabia: the Thugbah studyS al Rajeh, O Bademosi, H Ismail, et al.
Saudi Journal of Kidney Diseases and Transplantation : an Official Publication of the Saudi Center for Organ Transplantation, Saudi Arabia|April 15, 2008
Neurological disorders in renal transplant recipientsG Al Ghamdi, A Awada, D Z Tanimu, et al.
IEEE Transactions on Bio-Medical Engineering|September 15, 1998
Effect of conductivity uncertainties and modeling errors on EEG source localization using a 2-D modelK A Awada, D R Jackson, S B Baumann, et al.
European Journal of Cancer (Oxford, England : 1990)|March 26, 2003
An EORTC-ECSG phase I study of LU 79553 administered every 21 or 42 days in patients with solid tumoursA Awada, R Thödtmann, M J Piccart, et al.
Clinical and Experimental Dermatology|November 29, 2005
High serum galectin-3 in advanced melanoma: preliminary resultsP Vereecken, K Zouaoui Boudjeltia, C Debray, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|June 18, 2010
Heterogeneity of metabolic response to systemic therapy in metastatic breast cancer patientsV Huyge, C Garcia, J Alexiou, et al.
British Journal of Cancer|May 6, 2008
Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation studyA Awada, J Albanell, P A Canney, et al.
Seminars in Oncology|October 1, 1996
An ongoing European organization for research and treatment of cancer crossover trial comparing single-agent paclitaxel and doxorubicin as first- and second-line treatment of advanced breast cancerM J Piccart-Gebhart, P Bruning, T Gamucci, et al.
Pageof 21

Showing results (151-160 of 210) with videos related to

Sort By:
Pageof 21
Medical Oncology (Northwood, London, England)|July 8, 2011
Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: an expert agreementC Porta, G Tortora, C Linassier, et al.
Anti-Cancer Drugs|May 29, 2004
Prolonged schedule of temozolomide (Temodal) plus liposomal doxorubicin (Caelyx) in advanced solid cancersA Awada, T Gil, F Sales, et al.
Neuroepidemiology|January 1, 1993
A community survey of neurological disorders in Saudi Arabia: the Thugbah studyS al Rajeh, O Bademosi, H Ismail, et al.
Saudi Journal of Kidney Diseases and Transplantation : an Official Publication of the Saudi Center for Organ Transplantation, Saudi Arabia|April 15, 2008
Neurological disorders in renal transplant recipientsG Al Ghamdi, A Awada, D Z Tanimu, et al.
IEEE Transactions on Bio-Medical Engineering|September 15, 1998
Effect of conductivity uncertainties and modeling errors on EEG source localization using a 2-D modelK A Awada, D R Jackson, S B Baumann, et al.
European Journal of Cancer (Oxford, England : 1990)|March 26, 2003
An EORTC-ECSG phase I study of LU 79553 administered every 21 or 42 days in patients with solid tumoursA Awada, R Thödtmann, M J Piccart, et al.
Clinical and Experimental Dermatology|November 29, 2005
High serum galectin-3 in advanced melanoma: preliminary resultsP Vereecken, K Zouaoui Boudjeltia, C Debray, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|June 18, 2010
Heterogeneity of metabolic response to systemic therapy in metastatic breast cancer patientsV Huyge, C Garcia, J Alexiou, et al.
British Journal of Cancer|May 6, 2008
Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation studyA Awada, J Albanell, P A Canney, et al.
Seminars in Oncology|October 1, 1996
An ongoing European organization for research and treatment of cancer crossover trial comparing single-agent paclitaxel and doxorubicin as first- and second-line treatment of advanced breast cancerM J Piccart-Gebhart, P Bruning, T Gamucci, et al.
Pageof 21